HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic
Interventions: DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Capecitabine
Sponsor: Theodoros Foukakis